Eye and Tissue Banks
The eye and tissue sector is the largest donation and transplantation sectors in Australia, with a significantly higher number of referrals compared to solid organ referrals.
Eye and tissue banks provide significant benefits within the health sector. Donations of eye and tissue can significantly improve the lives of recipients and in some cases, are life saving.
In Australia, eye and tissue donation and transplantation is regulated by the Therapeutic Goods Administration (TGA). The TGA implemented the Biologicals Regulatory Framework in May 2011 requiring eye and tissue banks to demonstrate quality controls and legislative compliance to gain entry on the Australian Register of Therapeutic Goods.
Eye and tissue banks in Australia include:
- ACT Bone Bank
- Australian Biotechnologies
- Donor Tissue Bank Victoria
- Hunter New England Bone Bank
- NSW Bone Bank
- NSW Lions Eye Bank
- Rachel Forster Bone Bank
- Sydney Heart Valve Bank
- Queensland Tissue Banks (incorporating Eye, Bone & Skin, Heart Valve)
- Queensland Bone & Skin Bank (Manager, Quality, Assessment and Development)
- Queensland Bone & Skin Bank (Manager, Production Research and Facility)
- Queensland Heart Valve Bank
- Queensland Eye Bank
- South Australian Tissue Bank
- South Australian Eye Bank
- Barwon Health Bone Bank
- Lions Eye Donation Service VIC
- PlusLife- Perth Bone & Tissue Bank
- Cell and Tissue Therapies WA
- WA Lions Eye Bank
The Organ and Tissue Authority (OTA) in collaboration with eye and tissue bank representatives completed a review of eye and tissue banking in Australia in 2011 and developed the Report on the options for more effective eye and tissue retrieval, processing and storage (the Report). The Report was endorsed by the Clinical, Technical and Ethical Principal Committee and the Australian Health Ministers Advisory Council in September 2011.
The Report provides information on the significant benefits within the health sector as a result of eye and tissue donations that significantly improve or save the lives of recipients. The Report also identified gaps which include the need for national education of eye and tissue bank staff; improved data collection and analysis; the need for national allocation and distribution of eye and tissue products; implementation of unique identifiers to enable timely traceability of products; consistency of national legislation and consistency of practice across banks.
A three staged approach has been adopted to address these gaps. Stage 1 consolidates and builds on work already done in the sector and includes development of nationally agreed data definitions and datasets; identification of a national data registry; development of an education program for eye and tissue bank staff and development of nationally consistent standards for retrieval, processing and storage. Stages 2 and 3 will progress the harmonisation and standardisation of legislation and protocols as well as review the national operational capacity in the eye and tissue sector.
The OTA is now well underway in progressing Stage 1 of the Report.